BioPlus Acquisition EBIT

The latest EBIT for BIOS is $-1.1M as of June 2023. That compares with $-560K in the prior-year period — down 89.5% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside BioPlus Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIOS's EBIT moved from $-560K to $-1.1M — a 89.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioPlus Acquisition's operating scale or balance-sheet position.

Against its sector companies, BIOS currently prints $-1.1M for EBIT, while the sector average sits near $-63M. That is roughly 98.3% above the sector mean. Large gaps often invite a closer look at BioPlus Acquisition's growth, margins, and balance sheet.

A EBIT figure of $-1.1M for BIOS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting BIOS's EBIT ($-1.1M), review year-over-year change from $-560K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.